Posted by Michael Wonder on 18 Oct 2020
First long-acting injectable antiretroviral therapy for HIV recommended for approval
16 October 2020 - EMA has recommended the granting of marketing authorisations for two new antiretroviral medicines, Rekambys (rilpivirine) and Vocabria injection (cabotegravir), to be used together for the treatment of patients with human immunodeficiency virus type 1infection.
The two medicines are the first antiretrovirals that come in a long-acting injectable formulation. This means that instead of daily pills, patients receive intramuscular injections monthly or every two months.
